Tirzepatide

What Tirzepatide is

Tirzepatide, also known by the development code LY3298176, is a first-in-class synthetic peptide engineered by Eli Lilly and Company to activate two distinct incretin hormone receptors simultaneously: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) ^[1]. Unlike earlier incretin-based therapies that targeted only the GLP-1 pathway, tirzepatide was designed as a 'twincretin' or dual incretin receptor agonist, making it pharmacologically distinct from all predecessors ^[2]. The molecule is an acylated 39-amino acid peptide; acylation was deliberately incorporated to extend its half-life and enable once-weekly administration in research settings, while the fatty acid chain also promotes binding to serum albumin, creating a depot effect that modulates receptor engagement over time ^[3].

The compound emerged from a broader research programme exploring whether combining GIP agonism with GLP-1 agonism could improve on the already established metabolic benefits of selective GLP-1 receptor agonists ^[4]. Structural biology work later revealed that tirzepatide's interaction with GLP-1R and GIPR is not perfectly symmetrical: it exhibits a greater degree of receptor occupancy at the GIP receptor than at the GLP-1 receptor, and at the GLP-1 receptor it shows biased signalling, preferring cyclic AMP (cAMP) generation over β-arrestin recruitment ^[5]. This 'imbalanced and biased' pharmacological profile is considered central to understanding why tirzepatide may outperform selective GLP-1 receptor agonists in metabolic outcomes ^[5].

What it is being researched for

1. Obesity and body weight reduction

The most extensively studied application of tirzepatide is the reduction of excess body weight in adults with overweight or obesity. The SURMOUNT clinical trial programme (phases 1–5) provides the largest body of human evidence. In the SURMOUNT-1 trial, participants without diabetes who received tirzepatide lost up to 20.9% of baseline body weight at 72 weeks, compared with 3.1% in the placebo group ^[6]. Subsequent SURMOUNT-3 data confirmed that tirzepatide produced clinically meaningful additional weight loss in participants who had already achieved at least 5% weight reduction through an intensive lifestyle programme ^[7]. In the head-to-head SURMOUNT-5 trial—the first direct comparison of the leading incretin therapies—tirzepatide delivered significantly greater sustained weight loss than semaglutide over 72 weeks in adults with obesity or overweight and comorbidities ^[8]. Body composition analyses from SURMOUNT-1 showed that while tirzepatide reduced lean mass modestly (~10.9%), the reduction in total fat mass was far more pronounced (~33.9%), suggesting preferential adipose-tissue loss ^[9].

2. Type 2 diabetes and glycaemic control

Five phase 3 clinical trials in the SURPASS programme (SURPASS-1 through SURPASS-5) evaluated tirzepatide in adults with T2DM and together constitute one of the most comprehensive T2DM trial datasets for any single agent. Across these trials, tirzepatide produced substantial, dose-dependent reductions in HbA1c (up to 2.58%) and body weight (up to 11.7 kg) that exceeded those achieved by semaglutide, insulin degludec, and titrated basal insulin ^[2]. In SURPASS-2, tirzepatide outperformed injectable semaglutide 1 mg across all three investigated doses in reductions of both HbA1c and body weight ^[4]. A post hoc pooled analysis of SURPASS-1–5 also documented that tirzepatide was associated with consistent improvements in HbA1c regardless of age at T2DM diagnosis, with older adults (≥65 years, BMI <30 kg/m²) experiencing clinically meaningful HbA1c reductions ^[10]. Real-world evidence from patients with T2DM initiating tirzepatide in clinical practice has been broadly consistent with trial findings ^[11].

3. Cardiovascular and heart failure outcomes

Research into tirzepatide's cardiovascular effects has expanded substantially with the SUMMIT trial, a phase 3, international, double-blind, randomised, placebo-controlled study enrolling 731 patients with HFpEF and obesity. SUMMIT demonstrated that tirzepatide reduced the combined endpoint of cardiovascular death or worsening heart failure events by approximately 38%, and improved health status, exercise tolerance (6-minute walk distance), and quality-of-life scores versus placebo ^[12]. A mechanistic secondary analysis of SUMMIT showed that tirzepatide treatment reduced systolic blood pressure, estimated blood volume, and C-reactive protein levels—findings consistent with relief of circulatory volume-pressure overload and systemic inflammation ^[13]. Imaging substudies further documented reductions in left ventricular mass and paracardiac adipose tissue, which researchers have proposed as a contributing mechanism to the reduction in heart failure events ^[14]. The ongoing SURPASS-CVOT is designed to provide longer-term, hard cardiovascular endpoint data ^[15].

4. Metabolic dysfunction-associated steatotic liver disease (MASLD)

Tirzepatide is under active investigation for metabolic liver disease, including MASLD and its more severe form metabolic dysfunction-associated steatohepatitis (MASH). A phase 2 trial (Loomba et al., 2024) in participants with biopsy-confirmed MASH and moderate-to-severe fibrosis found that 44% of participants in the lowest tirzepatide group achieved MASH resolution without worsening of fibrosis at 52 weeks, compared with 10% in the placebo group ^[16]. At the mechanistic level, preclinical work in mice fed high-fat or high-fat/high-fructose/high-cholesterol diets showed that tirzepatide significantly reduced hepatic lipid accumulation, liver weight, serum glucose, and hepatic triglyceride and cholesterol content, partly through downregulation of the fatty acid transporter CD36 and odorant-binding protein 2A ^[17]. A large real-world propensity-matched cohort study found tirzepatide was associated with substantially lower rates of mortality, hospitalisation, and major adverse liver outcomes compared with SGLT2 inhibitors among patients with MASLD ^[18].

5. Beta-cell function and insulin sensitivity

A key area of mechanistic research concerns how tirzepatide's dual receptor agonism affects pancreatic beta-cell function and peripheral insulin sensitivity beyond what is explained by weight loss alone. Post hoc analyses of SURPASS trial data showed that tirzepatide improved markers of insulin sensitivity and beta-cell function to a greater extent than the selective GLP-1 receptor agonist dulaglutide, and that insulin-sensitising effects were only partly attributable to weight loss, suggesting dual receptor agonism confers distinct mechanisms of glycaemic control ^[19]. Biomarker analyses indicated that tirzepatide-dependent increases in insulin growth factor binding proteins (IGFBP-1 and IGFBP-2) point to distinct insulin-sensitising functions compared with selective GLP-1 receptor agonists ^[19]. Mechanistic studies in primary pancreatic islets have also demonstrated that tirzepatide's biased agonism at the GLP-1 receptor—favouring cAMP over β-arrestin signalling—appears to enhance the insulin secretory response compared with native GLP-1 ^[5].

6. Renal outcomes and albuminuria

Emerging research suggests tirzepatide may exert beneficial effects on kidney health in individuals with T2DM. A pooled post hoc analysis across SURPASS-1 through SURPASS-5 (>5,200 participants) observed a consistently greater decrease in urine albumin-to-creatinine ratio (UACR) associated with tirzepatide versus all comparators, including placebo, insulin, and semaglutide ^[20]. In SURPASS-4, tirzepatide compared with insulin glargine was associated dose-dependently with reduced albuminuria and attenuated estimated glomerular filtration rate (eGFR) decline in participants with T2DM at high cardiovascular risk ^[20]. SUMMIT trial subanalyses further showed that reductions in worsening heart failure events with tirzepatide appeared comparable in participants with and without pre-existing chronic kidney disease ^[21].

7. Neurological and quality-of-life research

Emerging areas of research include potential neurological applications of tirzepatide, given that GLP-1 and GIP receptors are expressed in brain regions relevant to appetite regulation and neuroprotection. A broad review published in PMC (2025) highlighted preclinical and early evidence that tirzepatide's incretin receptors are expressed in areas linked to Alzheimer's and Parkinson's disease pathophysiology, though human trial data in these conditions remain limited and largely exploratory ^[22]. On the well-established side, multiple analyses from the SURMOUNT programme have demonstrated that tirzepatide treatment is associated with improved health-related quality of life (HRQoL), with greater improvements seen among participants achieving larger weight reductions and in those reporting physical function limitations at baseline ^[23].

How it is thought to work

Tirzepatide achieves its metabolic effects by simultaneously activating two G protein-coupled receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) ^[1]. Both receptors are expressed on pancreatic beta cells, and their activation augments glucose-stimulated insulin secretion—the classical incretin effect ^[4]. However, tirzepatide's pharmacology is not a simple additive combination of two receptor agonists. Receptor occupancy modelling has shown that tirzepatide engages the GIPR to a greater degree than the GLP-1R at clinically studied concentrations, establishing what researchers describe as an 'imbalanced' mechanism ^[5]. Furthermore, at the GLP-1R, tirzepatide exhibits biased agonism: it preferentially promotes intracellular cAMP accumulation rather than β-arrestin recruitment, and drives far less receptor internalisation than native GLP-1 ^[5]. Experiments in primary islets indicate that this bias enhances the insulin secretory response, because β-arrestin1 limits the insulin response to native GLP-1 but not to GIP or tirzepatide ^[5].

Beyond the pancreas, GLP-1 receptor activation increases satiety both centrally—through hypothalamic signalling—and peripherally by slowing gastric emptying ^[4]. The GIP component adds further metabolic benefit: GIP receptor activation has been shown to improve insulin sensitivity by reducing ectopic intramuscular fat deposition and promoting fat storage in white adipose tissue, which in turn reduces lipid overflow to the liver ^[4]. Together, these converging pathways explain why an agonist targeting both GLP-1R and GIPR produces greater reductions in blood glucose and body weight than either selective agonist alone ^[4]. In the cardiovascular context, mechanistic studies from the SUMMIT trial suggest tirzepatide additionally reduces circulating blood volume, systemic inflammation (as measured by high-sensitivity CRP), and myocardial stress markers, pointing to cardiorenal protective mechanisms that extend beyond glycaemic and weight effects ^[13].

Where the evidence stands

The human clinical evidence base for tirzepatide is unusually large for a relatively recent peptide. The SURPASS programme (five major phase 3 trials in T2DM) demonstrated robust, dose-dependent reductions in HbA1c and body weight superior to multiple active comparators including semaglutide and insulin ^[2]. The SURMOUNT programme (multiple phase 3 obesity trials) extended these findings to individuals without diabetes, with SURMOUNT-1 showing up to 20.9% body weight reduction at 72 weeks versus 3.1% with placebo ^[6], and SURMOUNT-5 establishing superiority over semaglutide head-to-head ^[8]. The SUMMIT trial provided phase 3 outcomes data in HFpEF, showing a 38% reduction in the composite of cardiovascular death or worsening heart failure events ^[12]. A phase 2 trial by Loomba et al. (2024) in MASH with fibrosis reported MASH resolution rates of 44% versus 10% for placebo ^[16]. Collectively, these large-scale randomised trials in tens of thousands of participants represent a high level of clinical evidence.

However, important gaps and limitations remain. Most individual SURPASS and SURMOUNT trials had follow-up periods of 40–88 weeks; ultra-long-term safety data beyond two to three years are still accumulating, and SURPASS-CVOT is ongoing ^[15]. Special populations, including those with severe renal impairment, remain under-studied ^[15]. The mechanisms underlying tirzepatide's superiority over selective GLP-1 receptor agonists are not fully resolved—particularly the precise contribution of GIPR agonism in humans versus rodents, where GIP's effects on body weight differ markedly from those seen in human studies ^[2]. Preclinical work in cell and animal models has been essential for mechanistic understanding (e.g., CD36/OBP2A downregulation in MASLD mouse models ^[17], islet β-arrestin1 experiments ^[5]), but direct translation of these findings to clinical magnitude of benefit requires ongoing human validation. The potential for GLP-1R/GIPR signalling in neurological disease (Alzheimer's, Parkinson's) also remains at an early, largely preclinical, exploratory stage ^[22].

Frequently asked questions

What is tirzepatide and how is it different from semaglutide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin hormone receptors simultaneously, whereas semaglutide targets only the GLP-1 receptor. Head-to-head clinical trials such as SURPASS-2 and SURMOUNT-5 have shown tirzepatide produces greater reductions in both blood glucose and body weight than semaglutide. Researchers attribute this advantage to tirzepatide's additional GIP receptor activation and its biased signalling profile at the GLP-1 receptor.

What does research say about tirzepatide and weight loss?

Multiple large phase 3 trials in the SURMOUNT programme document substantial weight reductions. In SURMOUNT-1, participants without diabetes lost up to 20.9% of baseline body weight at 72 weeks compared with 3.1% for placebo. Body composition analyses suggest the majority of lost mass is fat rather than lean tissue. These results represent some of the largest weight reductions observed in randomised clinical trials of any pharmacological agent.

Is tirzepatide only studied for diabetes?

No. While it was first investigated in type 2 diabetes within the SURPASS programme, research has expanded to obesity management, heart failure with preserved ejection fraction (HFpEF), metabolic liver disease (MASLD/MASH), chronic kidney disease, and exploratory neurological indications. The SUMMIT trial specifically studied its effects in patients with obesity-related HFpEF, finding a significant reduction in worsening heart failure events.

How does tirzepatide work on the GIP and GLP-1 receptors?

Tirzepatide binds to and activates both the GIP receptor and the GLP-1 receptor, which are G protein-coupled receptors expressed in the pancreas, brain, adipose tissue, and other organs. At the GLP-1 receptor, tirzepatide shows biased signalling, preferring cAMP generation over β-arrestin recruitment, which appears to enhance insulin secretion. Its greater engagement of the GIP receptor than the GLP-1 receptor is considered part of what gives tirzepatide its distinct pharmacological profile.

What are the main side effects of tirzepatide observed in clinical trials?

Across SURPASS and SURMOUNT clinical trials, the most commonly reported adverse events were gastrointestinal in nature—primarily nausea, vomiting, and diarrhoea—consistent with the side effect profile of GLP-1 receptor agonists. These events were generally described as mild to moderate and transient. The risk of clinically significant hypoglycaemia was reported as low in trials that did not include insulin co-administration.

What does tirzepatide research show about heart failure?

The SUMMIT phase 3 trial, which enrolled 731 patients with obesity-related HFpEF, found that tirzepatide reduced the composite endpoint of cardiovascular death or worsening heart failure events by approximately 38% versus placebo. Mechanistic analyses showed reductions in estimated blood volume, systolic blood pressure, and inflammatory markers. Improvements in exercise tolerance and quality-of-life scores were also documented.

What is the current status of tirzepatide research in liver disease?

A phase 2 randomised trial by Loomba et al. (2024) in participants with biopsy-confirmed MASH and moderate-to-severe fibrosis found that tirzepatide achieved MASH resolution without worsening of fibrosis in 44% of participants in the lowest-dose group versus 10% in the placebo group. Preclinical mouse studies have identified downregulation of lipid transporter proteins (CD36 and OBP2A) as a potential mechanism. Phase 3 investigation in MASLD/MASH is ongoing.

Can tirzepatide help people who carry genetic causes of obesity, such as MC4R mutations?

Research from the SURMOUNT-1 trial examined participants who carried pathogenic mutations in the MC4R gene, the most common monogenic cause of obesity. The study found that weight-loss trajectories over 72 weeks were comparable between MC4R mutation carriers and non-carriers in the treatment arm, suggesting tirzepatide's mechanisms of action may be effective even when a common genetic driver of obesity is present.

Does tirzepatide research cover effects on kidney function?

Yes. A pooled post hoc analysis of SURPASS-1 through -5 (>5,200 participants with T2DM) found that tirzepatide was consistently associated with a greater reduction in urine albumin-to-creatinine ratio versus all comparators, including placebo, insulin, and semaglutide. SURPASS-4 data specifically suggested tirzepatide may slow eGFR decline in patients at high cardiovascular risk, and SUMMIT subanalyses indicated benefits were preserved in participants with pre-existing chronic kidney disease.

Are there ongoing clinical trials studying tirzepatide?

Yes. The SURPASS-CVOT trial is designed to assess long-term cardiovascular outcomes in adults with T2DM and established atherosclerotic cardiovascular disease. The SYNERGY-NASH trial is investigating tirzepatide in metabolic steatohepatitis. Various other registered trials continue to explore its effects in special populations, combination approaches, and disease-specific contexts. Researchers and clinicians have identified remaining knowledge gaps around long-term safety beyond two to three years and effects in populations with severe renal impairment.

Glossary

GLP-1 (Glucagon-Like Peptide-1)

An incretin hormone secreted from intestinal L-cells in response to nutrient ingestion that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

An incretin hormone released from duodenal and jejunal K-cells after meals that amplifies insulin secretion in a glucose-dependent manner and also influences adipose tissue metabolism and insulin sensitivity.

Dual agonist (twincretin)

A single molecule engineered to activate two distinct receptor types simultaneously; tirzepatide is the first approved dual GIP/GLP-1 receptor agonist and is sometimes called a 'twincretin'.

Biased agonism

A property of some receptor ligands whereby they preferentially activate one intracellular signalling pathway (e.g., cAMP) over another (e.g., β-arrestin recruitment) at the same receptor, potentially producing a distinct pharmacological outcome.

HbA1c (Glycated Haemoglobin)

A blood biomarker reflecting average blood glucose concentration over approximately 2–3 months, widely used as the primary endpoint for glycaemic control in diabetes clinical trials.

HFpEF (Heart Failure with Preserved Ejection Fraction)

A form of heart failure in which the left ventricle pumps normally but is abnormally stiff, strongly associated with obesity and metabolic dysfunction, and the focus of tirzepatide's SUMMIT trial.

MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

The current preferred umbrella term for liver conditions characterised by excess hepatic fat accumulation linked to metabolic risk factors such as obesity and insulin resistance, formerly termed non-alcoholic fatty liver disease (NAFLD).

UACR (Urine Albumin-to-Creatinine Ratio)

A clinical biomarker used to detect and monitor kidney damage by measuring the ratio of albumin to creatinine in urine, with elevated levels indicating glomerular injury or early diabetic kidney disease.

References

1. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist — JCI Insight (2020)
2. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction — Cardiovascular Diabetology (2022)
3. Understanding the activation mechanism of GLP-1R/GIPR by dual agonist Tirzepatide via molecular dynamics and protein-peptide binding — International Journal of Biological Macromolecules (2025)
4. Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health — PMC / PubMed Central (2025)
5. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes — Journal of Clinical Endocrinology & Metabolism (2021)
6. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial — Nature Medicine / PMC (2023)
7. Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial — Applied Clinical Trials Online (2025)
8. Tirzepatide for overweight and obesity management — Expert Opinion on Pharmacotherapy (2024)
9. Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency — PMC / Nature Medicine (2025)
10. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials — Diabetes Therapy / Springer (2025)
11. Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes — PMC / PubMed Central (2025)
12. Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management — PMC / PubMed Central (2025)
13. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial — Nature Medicine (2025)
14. SUMMIT: Tirzepatide Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity — American College of Cardiology (2024)
15. Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health — PMC / Frontiers in Endocrinology (2024)